Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is a medical technology company with a comprehensive portfolio of innovative orthobiologics and spinal implant systems. The company's consistent product growth and strong financials, including a projected 10% CAGR through FY28, provide a strong foundation for success in the future. Furthermore, recent strategic acquisitions and partnerships, such as the Dilon Technologies agreement and the sale of its Coflex, CoFix, and OUS businesses, showcase the management team's commitment to profitable growth and the potential for future upside. With shares trading at a discount to peers and the company's clear focus on expanding its global presence, we believe Xtant Medical Holdings presents a compelling investment opportunity with limited downside risk.

Bears say

Xtant Medical Holdings is facing significant challenges, starting with the ending of their OEM opportunities from licensing on SimpliMax's Q-code. Additionally, with competition, lower legacy performance, and a potential need for additional capital, combined with the softer-than-expected procedure environment, the company is at risk for decreased revenue and financial instability. This negative outlook is further supported by the fact that the company's key financial metrics, such as revenue and operating margin, have been declining over the past few years and are expected to continue on this downward trend in the near future.

XTNT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 1 analysts, XTNT has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.